StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) stock

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.48−0.23 (-0.22%)

Close on Nov 18, 2026Market cap $180.79BP/E 33.6Yield 2.30%

Abbott Laboratories operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Abbott Laboratories's operating income for the twelve months ending Jun 30, 2026 was $7.35B, down 2.2% year over year. For fiscal 2025 it was $8.05B, up 18.0% from the year before. Over ten years it grew 10.9% a year on average. The highest annual figure on record is $8.43B in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.05B+18.0%
FY2024Dec 31, 2024$6.83B+5.4%
FY2023Dec 31, 2023$6.48B-22.5%
FY2022Dec 31, 2022$8.36B-0.7%
FY2021Dec 31, 2021$8.43B+57.3%
FY2020Dec 31, 2020$5.36B+18.2%
FY2019Dec 31, 2019$4.53B+24.2%
FY2018Dec 31, 2018$3.65B+133.4%
FY2017Dec 31, 2017$1.56B-48.3%
FY2016Dec 31, 2016$3.03B+5.5%
FY2015Dec 31, 2015$2.87B+10.3%
FY2014Dec 31, 2014$2.60B+21.8%
FY2013Dec 31, 2013$2.13B+56.8%
FY2012Dec 31, 2012$1.36B-16.5%
FY2011Dec 31, 2011$1.63B-73.2%
FY2010Dec 31, 2010$6.09B-2.4%
FY2009Dec 31, 2009$6.24B+9.5%
FY2008Dec 31, 2008$5.69B+24.4%
FY2007Dec 31, 2007$4.58B–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.69B-17.5%
Q1 FY2026Mar 31, 2026$1.35B-20.6%
Q4 FY2025Dec 31, 2025$2.25B+17.8%
Q3 FY2025Sep 30, 2025$2.06B+10.7%
Q2 FY2025Jun 30, 2025$2.05B+22.9%
Q1 FY2025Mar 31, 2025$1.69B+22.2%
Q4 FY2024Dec 31, 2024$1.91B+7.4%
Q3 FY2024Sep 30, 2024$1.86B+12.9%
Q2 FY2024Jun 30, 2024$1.67B+8.2%
Q1 FY2024Mar 31, 2024$1.39B-8.2%
Q4 FY2023Dec 31, 2023$1.78B+36.5%
Q3 FY2023Sep 30, 2023$1.65B-6.9%
Q2 FY2023Jun 30, 2023$1.54B-35.1%
Q1 FY2023Mar 31, 2023$1.51B-48.2%
Q4 FY2022Dec 31, 2022$1.30B-45.2%
Q3 FY2022Sep 30, 2022$1.77B-30.5%
Q2 FY2022Jun 30, 2022$2.38B+70.7%
Q1 FY2022Mar 31, 2022$2.91B+38.1%
Q4 FY2021Dec 31, 2021$2.38B-2.2%
Q3 FY2021Sep 30, 2021$2.55B+70.3%
Q2 FY2021Jun 30, 2021$1.39B+107.1%
Q1 FY2021Mar 31, 2021$2.11B+178.2%
Q4 FY2020Dec 31, 2020$2.43B+75.1%
Q3 FY2020Sep 30, 2020$1.50B+24.8%
Q2 FY2020Jun 30, 2020$672.00M-44.3%
Q1 FY2020Mar 31, 2020$758.00M+2.6%
Q4 FY2019Dec 31, 2019$1.39B+19.2%
Q3 FY2019Sep 30, 2019$1.20B+20.4%
Q2 FY2019Jun 30, 2019$1.21B+36.7%
Q1 FY2019Mar 31, 2019$739.00M+21.5%
Q4 FY2018Dec 31, 2018$1.17B+79.0%
Q3 FY2018Sep 30, 2018$995.00M+29.4%
Q2 FY2018Jun 30, 2018$882.00M+128.5%
Q1 FY2018Mar 31, 2018$608.00M–
Q4 FY2017Dec 31, 2017$651.00M-17.5%
Q3 FY2017Sep 30, 2017$769.00M-14.3%
Q2 FY2017Jun 30, 2017$386.00M–
Q1 FY2017Mar 31, 2017-$242.00M–
Q4 FY2016Dec 31, 2016$789.00M–
Q3 FY2016Sep 30, 2016$897.00M–

More Abbott Laboratories figures

See a number that looks wrong?